New Studies Question Whether Novel Anti-Cancer Drugs Are Worth Their Extra Cost
A European study found no correlation between cancer drug cost and patient benefit delivered (based on ESMO & ASCO frameworks). Time to consider remuneration by results for new cancer drugs?
“Cost is one of the main reasons why patients are denied access to the newer anti-cancer drugs, and we can use the ESMO-MCBS to clearly demonstrate which drugs provide greatest benefit for patients. By showing which drugs are most likely to be worth the higher cost, we can hopefully improve access to the drugs with greatest value so that patients receive standardised, optimal therapy wherever they live,” Kiesewetter concluded.